NCM
AMRX icon

Nantahala Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Nantahala Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.3M Sell
2,268,751
-575,357
-20% -$7.88M 1.3% 13
2026
Q1 		$35.4M Buy
2,844,108
+396,592
+16% +$5.32M 1.3% 19
2025
Q4 		$30.8M Sell
2,447,516
-1,777,048
-42% -$20.3M 1.02% 23
2025
Q3 		$42.3M Sell
4,224,564
-142,874
-3% -$1.28M 1.47% 15
2025
Q2 		$35.3M Buy
4,367,438
+558,877
+15% +$4.21M 1.38% 12
2025
Q1 		$31.9M Buy
3,808,561
+143,032
+4% +$1.19M 1.27% 13
2024
Q4 		$29M Buy
3,665,529
+995,586
+37% +$8.35M 1.25% 15
2024
Q3 		$22.2M Hold
2,669,943
– – 1.12% 18
2024
Q2 		$17M Buy
2,669,943
+50,000
+2% +$317K 0.99% 19
2024
Q1 		$15.9M Buy
2,619,943
+285,546
+12% +$1.61M 0.91% 24
2023
Q4 		$14.2M Buy
2,334,397
+121,640
+5% +$542K 0.85% 23
2023
Q3 		$9.34M Buy
2,212,757
+63,452
+3% +$237K 0.8% 31
2023
Q2 		$6.66M Buy
2,149,305
+1,649,305
+330% +$3.51M 0.64% 40
2023
Q1 		$695K Buy
+500,000
New +$996K 0.05% 101

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Nantahala Capital Management's AMRX Position: Q2 2026 in Review

Nantahala Capital Management reduced its Amneal Pharmaceuticals (AMRX) stake by 20% in Q2 2026, selling an estimated $7.88M and leaving 2,268,751 shares worth $39.3M. The position accounts for 1.3% of the portfolio, ranked #13.

Nantahala Capital Management first reported a position in AMRX in Q1 2023 and has held it in 14 quarters since. The position peaked at $42.3M in Q3 2025. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Nantahala Capital Management held 2,268,751 shares of Amneal Pharmaceuticals worth $39.3M as of Q2 2026.
  • Nantahala Capital Management sold 575,357 Amneal Pharmaceuticals shares in Q2 2026, an estimated $7.88M.
  • Amneal Pharmaceuticals made up 1.3% of Nantahala Capital Management's portfolio in Q2 2026, its #13 holding.
  • Nantahala Capital Management first reported a position in Amneal Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • Nantahala Capital Management's Amneal Pharmaceuticals position peaked at $42.3M in Q3 2025.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.